

LETTER TO THE EDITOR - OBSERVATION LETTER

[\[Download PDF\]](#)

Year : 2016 | **Volume** : 82 | **Issue** : 1 | **Page** : 81-84

Could co-infection with *Anaplasma* play a role in *Borrelia*-associated primary cutaneous marginal zone B-cell lymphomas?

Serena Bonin¹, Giuseppe Stinco², Maria Martina Patriarca², Sara Trevisini¹, Nicola di Meo¹, Giusto Trevisan¹,

¹ Department of Medical Sciences, Unit of Dermatology, University of Trieste, Trieste, Italy

² Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy

Correspondence Address:

Serena Bonin

Department of Medical Sciences, Unit of Dermatology, Cattinara Hospital, Strada di Fiume, 447, 34149 Trieste
Italy

How to cite this article:

Bonin S, Stinco G, Patriarca MM, Trevisini S, di Meo N, Trevisan G. Could co-infection with *Anaplasma* play a role in *Borrelia*-associated primary cutaneous marginal zone B-cell lymphomas?. Indian J Dermatol Venereol Leprol 2016;82:81-84

How to cite this URL:

Bonin S, Stinco G, Patriarca MM, Trevisini S, di Meo N, Trevisan G. Could co-infection with *Anaplasma* play a role in *Borrelia*-associated primary cutaneous marginal zone B-cell lymphomas?. Indian J Dermatol Venereol Leprol [serial online] 2016 [cited 2016 Nov 9];82:81-84

Available from: <http://www.ijdv.com/text.asp?2016/82/1/81/171011>

Full Text

Sir,

Borrelia burgdorferi, the causative agent of Lyme disease, infects humans through Ixodes tick bites. In Europe, several *Borrelia* strains have been associated with primary cutaneous B-cell lymphoma, in particular, cutaneous marginal zone B-cell lymphoma.[1] It has already been reported that clinical regression of *B. burgdorferi*-associated cutaneous marginal zone B-cell lymphomas did not occur after specific antimicrobial therapy although polymerase chain reaction (PCR) analysis for *Borrelia* became negative.[2] Persistence of the lymphoma could be related to host factors or another unknown antigenic stimulation unresponsive to antimicrobial treatment. Significant co-infections in Lyme disease could be due to microorganisms transmitted by the same vector. In our province, (Trieste, North-Eastern Italy) co-infection of *Borrelia* with *Anaplasma phagocytophilum* and *Rickettsia helvetica* is rather frequent: 15 (3.5%) patients tested positive to *Borrelia* and *A. phagocytophilum* during 2013. To further investigate this association, we carried out a study investigating the presence of co-infections in patients with proven *Borrelia*-related cutaneous marginal zone B-cell lymphoma.

We report on four consecutive patients with the morphological features of primary cutaneous marginal zone B-cell lymphoma.

The first three patients participating in this study had previously been reported.[3] Patients were investigated for the presence of *B. burgdorferi*, *A. phagocytophilum* and *R. helvetica* with conventional serology and for *Borrelia* also by PCR.[3]

A 62-year-old man presented with cutaneous marginal zone B-cell lymphoma characterized by pink, non-tender, pruritic skin nodules on his right inner thigh [Figure 1]. Biopsy showed a nodular lymphoid proliferation of small lymphocytes within the dermis. Clonality of B lymphocytes was revealed by Ki67 staining. Both serologic tests (ELISA IgG and Western blot) and PCR assays for *B. burgdorferi* were positive. Serologic analysis for IgG antibodies to *A. phagocytophilum* was positive while the test was negative for *R. helvetica*. {Figure 1}

A 46-year-old woman presented with five itchy erythematous, non-tender and painless papules on her right leg [Figure 1]. Routine laboratory investigations were normal. Biopsy of the lesion showed a dense nodular infiltrate of lymphocytes separated from the epidermis by a Grenz zone [Figure 2]. {Figure 2}

B-cell clonality was assessed by lambda and kappa light chain immunohistochemistry in frozen sections [Figure 2]. In view of these findings and the immunophenotype, a diagnosis of cutaneous marginal zone B-cell lymphoma was made.

Polymerase chain reaction assays for *Borrelia* DNA were positive both from biopsy and peripheral blood [Figure 2]. Serological investigations for *B. burgdorferi* and *R. helvetica* were negative while *A. phagocytophilum* serology proved to be IgG positive.

A healthy 35-year-old man developed an infiltrated erythematous patch on his right leg [Figure 1]. The patient had a previous history of Lyme disease.[3] Skin biopsy showed a top-heavy atypical lymphocytic infiltration involving the dermis and infiltrating the upper portion of subcutaneous fat. The characteristic Grenz zone of normal collagen was evident.

Polymerase chain reaction assays for *Borrelia* DNA were positive both from biopsy and peripheral blood. Serology for *Borrelia* was negative, but it was positive for *A. phagocytophilum* and *R. helvetica*.

A 36-year-old man developed a nodular erythematous lesion on his back [Figure 1] which was excised and a diagnosis of marginal cell lymphoma was made. Later, five small nodular lesions appeared around the surgical scar. Results of routine laboratory examinations were normal. The biopsy showed a top-heavy atypical lymphocytic infiltration with a Grenz zone.

Polymerase chain reaction assays for *Borrelia* DNA were positive both from peripheral blood and biopsy. Serology for *Borrelia* and *A. phagocytophilum* was positive, but negative for *R. helvetica*.

All four patients underwent antibiotic treatment with doxycycline, 100 mg twice a day for 20 days. Lymphomas were treated in all patients with electrochemotherapy as already reported.[3] A complete response was obtained in all patients after 4 weeks. During the follow-up period, three patients relapsed as reported in [Table 1].{Table 1}

The association between chronic infection with *Borrelia* and the development of cutaneous marginal zone B-cell lymphoma is conceptually and clinically similar to the one seen in B-cell lymphomas of the stomach, a proportion of which are associated with infection by *Helicobacter pylori*. Similarly, the suspected pathophysiology for the induction of lymphoma by *Borrelia* is chronic antigen-dependent immunostimulation triggering sustained lymphoid proliferation with oligoclonal and ultimately monoclonal B-cell selection.[4] It has been hypothesized that *H. pylori* eradication leads to the disappearance of intratumoral *H. pylori* specific T-cells and to lymphoma regression.[2] In the same way, complete regression of lymphoma lesions has been seen after antibiotic treatment for *B. burgdorferi*. [5]

Patients with *Borrelia*- related cutaneous marginal zone B-cell lymphoma unresponsive to antibiotic treatment may be subjected to other chronic antigen stimulation.[1] We focused on *A. phagocytophilum* and *R. helvetica* co-infections which are the most frequent microorganisms co-infected with *B. burgdorferi* by *Ixodes ricinus* in our area. We were unable to find any previous reports of the association between primary cutaneous B-cell

lymphoma and other infections concurrent with *Borrelia*. Our data show that co-infections occur in some patients with *Borrelia*-related lymphomas. The impact of concurrent infections in Lyme disease has not yet been fully clarified because multiple infections are difficult to analyse as it is usually impossible to establish the infection that plays a predominant role in the pathological process due to frequent overlapping of clinical symptoms caused by borreliosis and co-infections. We speculate that in case of *Borrelia*- related primary cutaneous B-cell lymphoma, multiple infections may influence the immune system by decreasing co-surveillance and favoring a chronic B-cell stimulation towards an oligo/monoclonal B-cell proliferation. This may result in resistance to antibiotic therapy or in a persisting and self-maintaining disease driven by unknown antigenic stimulation even after the eradication of bacteria.

Our study had limitations due to lack of facility to detect *A. phagocytophilum* in tissue biopsy to demonstrate the co-infection and that *Borrelia* infection was not confirmed by serology in two patients. Nevertheless, to strengthen our data, three distinct PCR analyses have been carried out for *Borrelia* in both blood and biopsies for all patients. We were also limited by our small sample size and single geographic area. However, our study stresses on performing more comprehensive analyses in order to establish if *A. phagocytophilum* should always be included in the serologic testing of patients with a history of tick bite, in patients with Lyme disease and *B. burgdorferi*-related cutaneous marginal zone B-cell lymphoma since co-infection could be more frequent than so far suspected.

Acknowledgments

This study was partially supported by the FRA2012 grant from the University of Trieste. The authors would thank Dr. Diego Signoretto and Dr. Eugenio Leonardo who provided us with histological images and details of the cases and Dr. Daniela Casotto who gave us information about co-infections of *Borrelia* and *A. phagocytophilum* in our population during 2013. The authors are also grateful to Dr. Valentina Melita for the language revision of the manuscript.

Financial support and sponsorship

This study was partially supported by the FRA2012 grant from the University of Trieste.

Conflicts of interest

There are no conflicts of interest.

References

- 1 Ponzoni M, Ferreri AJ, Mappa S, Pasini E, Govi S, Facchetti F, *et al.* Prevalence of *Borrelia burgdorferi* infection in a series of 98 primary cutaneous lymphomas. *Oncologist* 2011;16:1582-8.
- 2 Du MQ. MALT lymphoma: Recent advances in aetiology and molecular genetics. *J Clin Exp Hematop* 2007;47:31-42.
- 3 Gatti A, Stinco G, Trevisini S, di Meo N, Signoretto D, Leonardo E, *et al.* Electrochemotherapy as a novel treatment for primary cutaneous marginal zone B-cell lymphomas. *Dermatol Ther* 2014;27:244-7.
- 4 Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, *et al.* WHO-EORTC classification for cutaneous lymphomas. *Blood* 2005;105:3768-85.
- 5 Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: Recent advances in diagnosis and management. *Cancer Control* 2012;19:236-44.